A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients.
Adult
Aged
Aged, 80 and over
COVID-19
/ epidemiology
Female
Honduras
/ epidemiology
Humans
Immunologic Factors
/ administration & dosage
Intensive Care Units
Length of Stay
Male
Middle Aged
Respiration, Artificial
Respiratory Distress Syndrome
/ therapy
Retrospective Studies
Treatment Outcome
COVID-19 Drug Treatment
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
09
2020
accepted:
18
12
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
15
1
2021
Statut:
epublish
Résumé
COVID-19 pandemic has multifaceted presentations with rising evidence of immune-mediated mechanisms underplay. We sought to explore the outcomes of severe COVID-19 patients treated with a multi-mechanism approach (MMA) in addition to standard-of-care (SC) versus patients who only received SC treatment. Data were collected retrospectively for patients admitted to the intensive care unit (ICU). This observational cohort study was performed at five institutions, 3 in the United States and 2 in Honduras. Patients were stratified for MMA vs. SC treatment during ICU stay. MMA treatment consists of widely available medications started immediately upon hospitalization. These interventions target immunomodulation, anticoagulation, viral suppression, and oxygenation. Primary outcomes included in-hospital mortality and length of stay (LOS) for the index hospitalization and were measured using logistic regression. Of 86 patients admitted, 65 (76%) who had severe COVID-19 were included in the study; 30 (46%) patients were in SC group, compared with 35 (54%) patients treated with MMA group. Twelve (40%) patients in the SC group died, compared with 5 (14%) in the MMA group (p-value = 0.01, Chi squared test). After adjustment for gender, age, treatment group, Q-SOFA score, the MMA group had a mean length of stay 8.15 days, when compared with SC group with 13.55 days. ICU length of stay was reduced by a mean of 5.4 days (adjusted for a mean age of 54 years, p-value 0.03) and up to 9 days (unadjusted for mean age), with no significant reduction in overall adjusted mortality rate, where the strongest predictor of mortality was the use of mechanical ventilation. The finding that MMA decreases the average ICU length of stay by 5.4 days and up to 9 days in older patients suggests that implementation of this treatment protocol could allow a healthcare system to manage 60% more COVID-19 patients with the same number of ICU beds.
Identifiants
pubmed: 33411780
doi: 10.1371/journal.pone.0245025
pii: PONE-D-20-29696
pmc: PMC7790264
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245025Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist
Références
Autoimmun Rev. 2020 Jul;19(7):102568
pubmed: 32376398
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Crit Care Med. 2005 Jun;33(6):1266-71
pubmed: 15942342
Crit Care Explor. 2020 Apr 29;2(4):e0111
pubmed: 32426753
JAMA. 2020 Jun 9;323(22):2336-2338
pubmed: 32412581
EClinicalMedicine. 2020 Jun 20;24:100418
pubmed: 32766537
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
JAMA Netw Open. 2020 Jun 1;3(6):e2013136
pubmed: 32579195
Lancet. 2020 Aug 8;396(10248):381-389
pubmed: 32679111
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Resuscitation. 2014 May;85(5):587-94
pubmed: 24467882
Crit Care. 2020 May 26;24(1):256
pubmed: 32456663
Emerg Infect Dis. 2020 Jul;26(7):1470-1477
pubmed: 32255761
Crit Care. 2017 Mar 26;21(1):73
pubmed: 28342442
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
Lancet Respir Med. 2020 Jul;8(7):681-686
pubmed: 32473124
Clin Rheumatol. 2020 Jul;39(7):2085-2094
pubmed: 32474885
Cell Res. 2020 May;30(5):367-369
pubmed: 32346073
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
PLoS One. 2020 Aug 14;15(8):e0237131
pubmed: 32797054
Eur Heart J. 2020 Jun 7;41(22):2083-2088
pubmed: 32412631